Novartis (NVS) Stock Jumps 5% as MS Drug Delivers the Goods in Phase 3 Trials

TLDR

• Novartis stock rose nearly 5% after its oral MS drug remibrutinib met the main goals of two late-stage trials
• Remibrutinib beat teriflunomide (Sanofi’s Aubagio) in reducing relapse rates in relapsing multiple sclerosis patients
• The drug also showed meaningful improvement in slowing disability progression with no liver safety concerns
• Novartis paused eight trials of a separate experimental cell therapy, rap-cel, after three patient deaths due to a severe immune reaction
• Cancer trials were not affected by the rap-cel halt; Novartis plans to seek global regulatory approval for remibrutinib

Novartis stock jumped nearly 5% in early Tuesday trading after the company reported strong results from two late-stage trials of its oral multiple sclerosis drug, remibrutinib.

Novartis AG, NVS

The trials, REMODEL-1 and REMODEL-2, tested remibrutinib against teriflunomide, an existing oral MS therapy sold by Sanofi under the brand name Aubagio. Remibrutinib came out ahead on the primary goals in both studies.

… Continue reading the full article at the original source below.